A new kind of immune therapy has shown promise against the third most common blood cancer, multiple myeloma, researchers said Wednesday.The drug, elotuzumab, is a monoclonal antibody — a type of immune cell — made by Bristol Myers-Squibb, and was granted a breakthrough therapy designation by the US Food and Drug Administration last year.The phase III study involved 646 people who had multiple myeloma which returned after initial treatment with the standard therapy, lenalidomide and
Biologic therapy is a new form of therapy in many fields. You can equate that to a guided cruise missile. It is an attempt to minimise collateral damage. A monoclonal antibody is a protein structure that naturally occurs to repel infection by recognising a specific target. Modifying the selected target is the objective of immunotherapy. Knowing which target to choose is based on basic science research.
Unfortunately much of biologic therapy is expensive and will remain out of reach of most patients.